|
US5254539A
(en)
*
|
1985-08-26 |
1993-10-19 |
U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health |
Method of treating HIV with 2',3'-dideoxyinosine
|
|
DE3872635T2
(de)
*
|
1987-04-09 |
1992-12-17 |
Fisons Plc |
Pentamidin enthaltende pharmazeutische zusammensetzungen.
|
|
US5204113A
(en)
*
|
1987-04-09 |
1993-04-20 |
Fisons Plc |
Pharmaceutical compositions containing pentamidine
|
|
JPH02204489A
(ja)
*
|
1989-02-02 |
1990-08-14 |
Ajinomoto Co Inc |
易溶性2’,3’―ジデオキシイノシン、その製造法及び2’,3’―ジデオキシイノシン水性溶液の製造法
|
|
SE464168B
(sv)
*
|
1989-07-19 |
1991-03-18 |
Bo Fredrik Oeberg |
Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
|
|
US5026687A
(en)
*
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
|
US5162361A
(en)
*
|
1990-04-10 |
1992-11-10 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Method of treating diseases associated with elevated levels of interleukin 1
|
|
NZ243567A
(en)
*
|
1991-07-22 |
1995-04-27 |
Bristol Myers Squibb Co |
Pharmaceutical oral formulation of a dideoxy purine nucleoside comprising the nucleoside together with a water-insoluble antacid buffering composition
|
|
US5231174A
(en)
*
|
1992-02-27 |
1993-07-27 |
University Of Iowa Research Foundation |
2'isodideoxy-β-D-nucleosides as stable antiviral agents
|
|
US5696079A
(en)
*
|
1993-05-19 |
1997-12-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immunologic enhancement with intermittent interleukin-2 therapy
|
|
US5419900A
(en)
|
1993-05-19 |
1995-05-30 |
The United States Of America As Represented By The Department Of Of Health And Human Services |
Immunologic enhancement with intermittent interleukin-2 therapy
|
|
AU685128B2
(en)
*
|
1993-05-21 |
1998-01-15 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
|
|
EP0631783A1
(en)
*
|
1993-06-03 |
1995-01-04 |
Mitsubishi Chemical Corporation |
Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
|
|
US6093702A
(en)
*
|
1993-12-20 |
2000-07-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
|
|
US5521161A
(en)
*
|
1993-12-20 |
1996-05-28 |
Compagnie De Developpment Aguettant S.A. |
Method of treating HIV in humans by administration of ddI and hydroxycarbamide
|
|
US6130036A
(en)
*
|
1994-02-18 |
2000-10-10 |
University Of Washington |
Methods and compositions for screening for anti-AIDS drugs
|
|
US6338963B1
(en)
|
1994-07-25 |
2002-01-15 |
Neotherapeutics, Inc. |
Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
|
|
AU3216695A
(en)
*
|
1994-08-29 |
1996-03-22 |
University Of North Carolina At Chapel Hill, The |
Lipid analogs for treating viral infections
|
|
US7135584B2
(en)
*
|
1995-08-07 |
2006-11-14 |
Wake Forest University |
Lipid analogs for treating viral infections
|
|
US20020058636A1
(en)
*
|
1994-09-21 |
2002-05-16 |
Geoffrey P. Symonds |
Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
|
|
US20030180254A1
(en)
*
|
1995-05-26 |
2003-09-25 |
The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services |
Immunologic enhancement with intermittent interleukin-2 therapy
|
|
US5840711A
(en)
*
|
1995-06-21 |
1998-11-24 |
University Of Kentucky Research Foundation |
Compositions containing lithium inorganic salts and anti-viral drugs and method of treating viral infections such as acquired immunodeficiency syndrome
|
|
ES2214551T3
(es)
|
1995-11-02 |
2004-09-16 |
Schering Corporation |
Terapia de infusion continua de citocinas a baja dosis.
|
|
US6509313B1
(en)
|
1996-02-28 |
2003-01-21 |
Cornell Research Foundation, Inc. |
Stimulation of immune response with low doses of cytokines
|
|
US6528098B2
(en)
*
|
1996-10-22 |
2003-03-04 |
Advanced Viral Research Corp. |
Preparation of a therapeutic composition
|
|
US20030100532A1
(en)
*
|
1997-02-14 |
2003-05-29 |
Gary S. Jacob |
Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
|
|
US6114312A
(en)
*
|
1997-03-07 |
2000-09-05 |
Research Institute For Genetic And Human Therapy (R.I.G.H.T.) |
Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
|
|
KR100220645B1
(ko)
*
|
1997-07-04 |
1999-09-15 |
구광시 |
벤젠유도체의 제조방법
|
|
US6800616B2
(en)
*
|
1998-02-26 |
2004-10-05 |
Supergen, Inc. |
Treatment of HIV infections
|
|
US6303617B1
(en)
|
1998-05-04 |
2001-10-16 |
Neotherapeutics, Inc. |
Serotonin-like 9-substituted hypoxanthine and methods of use
|
|
WO2000016625A1
(en)
*
|
1998-09-23 |
2000-03-30 |
University Of Kentucky Research Foundation |
Antiviral drug compositions containing lithium inorganic salts
|
|
EP1207907B1
(en)
|
1999-08-13 |
2004-11-03 |
University Of Maryland Biotechnology Institute |
Compositions for treating viral infections, and methods therefor
|
|
US7026469B2
(en)
*
|
2000-10-19 |
2006-04-11 |
Wake Forest University School Of Medicine |
Compositions and methods of double-targeting virus infections and cancer cells
|
|
US6288069B1
(en)
|
1999-11-16 |
2001-09-11 |
Neotherapeutics, Inc. |
Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
|
|
US6407237B1
(en)
|
2001-02-21 |
2002-06-18 |
Neotherapeutics, Inc. |
Crystal forms of 9-substituted hypoxanthine derivatives
|
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
|
PL359169A1
(en)
|
2000-05-26 |
2004-08-23 |
Idenix (Cayman) Limited |
Methods and compositions for treating flaviviruses and pestiviruses
|
|
US6849735B1
(en)
*
|
2000-06-23 |
2005-02-01 |
Merck Eprova Ag |
Methods of synthesis for 9-substituted hypoxanthine derivatives
|
|
US6630490B2
(en)
|
2000-07-07 |
2003-10-07 |
Neotherapeutics, Inc. |
Methods for treatment of disease-induced peripheral neuropathy and related conditions
|
|
KR20090089922A
(ko)
|
2000-10-18 |
2009-08-24 |
파마셋 인코포레이티드 |
바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
|
|
US7309696B2
(en)
|
2000-10-19 |
2007-12-18 |
Wake Forest University |
Compositions and methods for targeting cancer cells
|
|
JP2005502580A
(ja)
*
|
2000-12-15 |
2005-01-27 |
フアーマセツト・リミテツド |
フラビウィルス感染治療用抗ウィルス薬
|
|
US6759427B2
(en)
*
|
2001-04-20 |
2004-07-06 |
Spectrum Pharmaceuticals, Inc. |
Synthesis and methods of use of tetrahydroindolone analogues and derivatives
|
|
KR20030041130A
(ko)
*
|
2001-05-29 |
2003-05-23 |
코닌클리케 필립스 일렉트로닉스 엔.브이. |
금속-세라믹 접착
|
|
US7994144B2
(en)
*
|
2001-07-10 |
2011-08-09 |
Johnson & Johnson Research Pty, Limited |
Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
|
|
US20030055249A1
(en)
*
|
2001-07-17 |
2003-03-20 |
Fick David B. |
Synthesis and methods of use of pyrimidine analogues and derivatives
|
|
MXPA04001917A
(es)
*
|
2001-08-31 |
2004-06-15 |
Thomson Licensing Sa |
Contador de secuencia para una corriente audio-visual.
|
|
AU2002330154A1
(en)
*
|
2001-09-28 |
2003-04-07 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
|
EP1480982A4
(en)
*
|
2002-02-14 |
2007-08-01 |
Pharmasset Inc |
MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES
|
|
AU2003247084B9
(en)
|
2002-06-28 |
2018-07-26 |
Centre National De La Recherche Scientifique |
Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
|
|
EP1545545A4
(en)
*
|
2002-08-01 |
2008-09-03 |
Pharmasset Inc |
COMPOUNDS WITH THE BICYCLO 4.2.1 NONAN SYSTEM FOR THE TREATMENT OF FLAVIVIRIDAE / I INFECTIONS
|
|
AU2003298658A1
(en)
|
2002-11-15 |
2004-06-15 |
Idenix (Cayman) Limited |
2'-branched nucleosides and flaviviridae mutation
|
|
RU2358979C2
(ru)
|
2003-05-30 |
2009-06-20 |
Фармассет, Инк. |
Модифицированные фторированные аналоги нуклеозида
|
|
ATE478886T1
(de)
|
2003-07-25 |
2010-09-15 |
Idenix Pharmaceuticals Inc |
Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
|
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
|
US20050187191A1
(en)
*
|
2004-02-20 |
2005-08-25 |
Kucera Louis S. |
Methods and compositions for the treatment of respiratory syncytial virus
|
|
US20050187192A1
(en)
*
|
2004-02-20 |
2005-08-25 |
Kucera Pharmaceutical Company |
Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
|
|
US20060040944A1
(en)
*
|
2004-06-23 |
2006-02-23 |
Gilles Gosselin |
5-Aza-7-deazapurine derivatives for treating Flaviviridae
|
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
|
ES2725457T3
(es)
|
2004-09-14 |
2019-09-24 |
Gilead Pharmasset Llc |
Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados
|
|
JP2008542369A
(ja)
*
|
2005-06-03 |
2008-11-27 |
アドバンスト バイラル リサーチ コープ. |
Avr118を用いて苦痛緩和医療を提供する方法
|
|
EP2518079A3
(en)
|
2006-04-11 |
2012-12-12 |
Novartis AG |
HCV/HIV inhibitors and their uses
|
|
WO2008035894A1
(en)
|
2006-09-19 |
2008-03-27 |
Sungkyunkwan University Foundation For Corporate Collaboration |
Antiviral agent against animal viruses
|
|
WO2008106166A2
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
|
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
US7964580B2
(en)
*
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
KR20110065440A
(ko)
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
|
CL2009002206A1
(es)
|
2008-12-23 |
2011-08-26 |
Gilead Pharmasset Llc |
Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
|
|
AR074897A1
(es)
*
|
2008-12-23 |
2011-02-23 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
|
MX2011006890A
(es)
*
|
2008-12-23 |
2011-07-20 |
Pharmasset Inc |
Analogos de nucleosidos.
|
|
WO2010101967A2
(en)
|
2009-03-04 |
2010-09-10 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole hcv polymerase inhibitors
|
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
AR077712A1
(es)
|
2009-08-05 |
2011-09-14 |
Idenix Pharmaceuticals Inc |
Inhibidores de serina proteasa macrociclica
|
|
WO2011063076A1
(en)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Methods of treating hepatitis c virus with oxoacetamide compounds
|
|
MY159958A
(en)
|
2009-12-18 |
2017-02-15 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
|
AP2012006535A0
(en)
|
2010-03-31 |
2012-10-31 |
Gilead Pharmasset Llc |
Stereoselective synthesis of phosphorous containing actives
|
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
|
TWI515000B
(zh)
|
2010-04-01 |
2016-01-01 |
伊迪尼克製藥公司 |
用於治療病毒感染之化合物及醫藥組合物
|
|
CN103179966B
(zh)
|
2010-10-08 |
2017-03-15 |
诺瓦提斯公司 |
磺酰胺ns3抑制剂的维生素e制剂
|
|
ES2716158T3
(es)
|
2010-11-30 |
2019-06-10 |
Gilead Pharmasset Llc |
2'-spiro-nucleótidos para el tratamiento de hepatitis C
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
TW201309690A
(zh)
|
2011-02-10 |
2013-03-01 |
Idenix Pharmaceuticals Inc |
巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途
|
|
WO2012107584A1
(en)
|
2011-02-11 |
2012-08-16 |
Universite Pierre Et Marie Curie (Paris 6) |
Methods for predicting outcome of a hepatitis virus infection
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
BR112014002365A2
(pt)
|
2011-08-03 |
2017-02-21 |
Cytheris |
interleucina-7 (il-7)
|
|
AU2012308900A1
(en)
|
2011-09-12 |
2013-05-09 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
US9403863B2
(en)
|
2011-09-12 |
2016-08-02 |
Idenix Pharmaceuticals Llc |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
|
HRP20180237T4
(hr)
|
2011-09-16 |
2020-12-11 |
Gilead Pharmasset Llc |
Metode za liječenje hcv-a
|
|
AR089650A1
(es)
|
2011-10-14 |
2014-09-10 |
Idenix Pharmaceuticals Inc |
Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
|
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
|
DE112012003510T5
(de)
|
2011-10-21 |
2015-03-19 |
Abbvie Inc. |
Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
CN104023726A
(zh)
|
2011-10-21 |
2014-09-03 |
艾伯维公司 |
用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
US9089574B2
(en)
|
2011-11-30 |
2015-07-28 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
|
WO2013133927A1
(en)
|
2012-02-13 |
2013-09-12 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
|
|
EP2852604B1
(en)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
MD20140134A2
(ro)
|
2012-05-22 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
|
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
|
ES2674980T3
(es)
|
2012-10-08 |
2018-07-05 |
Idenix Pharmaceuticals Llc |
Análogos de 2'-cloro nucleósidos para infección por VHC
|
|
EP2909223B1
(en)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Dinucleotide compounds for hcv infection
|
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
|
WO2014078427A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
|
EP2950786B1
(en)
|
2013-01-31 |
2019-11-27 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
|
EP2981542B1
(en)
|
2013-04-01 |
2021-09-15 |
Idenix Pharmaceuticals LLC |
2',4'-fluoro nucleosides for the treatment of hcv
|
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
|
US20150037282A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
|
EA201690473A1
(ru)
|
2013-08-27 |
2017-03-31 |
ГАЙЛИД ФАРМАССЕТ ЭлЭлСи |
Комбинированный состав двух противовирусных соединений
|
|
EP3046924A1
(en)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
|
EP3074399A1
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
|
WO2015095419A1
(en)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
4'-or nucleosides for the treatment of hcv
|
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
JP7129703B2
(ja)
|
2016-04-28 |
2022-09-02 |
エモリー ユニバーシティー |
アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
|
|
US20220160710A1
(en)
*
|
2019-03-08 |
2022-05-26 |
University Of Virginia Patent Foundation |
Compositions and methods for treating or preventing alzheimer's disease
|
|
KR102456699B1
(ko)
*
|
2020-11-19 |
2022-10-19 |
주식회사 오에이티씨 |
디다노신을 포함하는 신경염증성 질환 예방 또는 치료용 조성물
|